title: Bone morphogenetic protein-2 compared to autologous iliac crest bone graft in the treatment of long bone nonunion.
abstract: This retrospective study investigated the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) mixed with cancellous allograft on fracture healing compared to iliac crest autograft in the treatment of long bone nonunion. Eighty-nine patients with 93 established long bone nonunions treated between January 2002 and June 2004 at a single academic Level I trauma center were evaluated. Patients with clinical and radiographic evidence of failed fracture union underwent nonunion debridement, revision of fixation, and implantation at the nonunion site of either rhBMP-2 or the standard treatment autologous iliac crest bone graft. Union rate, operative time, estimated intraoperative blood loss, hospital length of stay, and postoperative infections were recorded. Nineteen nonunions received rhBMP-2 on a specialized carrier matrix (an absorbable collagen sponge) mixed with cancellous allograft, and 74 nonunions were treated with autologous iliac crest bone graft. There was no statistical difference in the rate of healing between treatment groups (68.4% vs 85.1%, respectively; P=.09). Incidence of postoperative infection was 16.2% after autologous iliac crest bone graft and 5.3% after rhBMP-2/absorbable collagen sponge (P=.22). Iliac crest autograft was associated with longer operative procedures (257.9±93.0 vs 168.9±86.5 minutes; P=.0007) and greater intraoperative blood loss (554.6±447.8 vs 331.6±357.2 mL; P=.01). These outcomes suggest that rhBMP-2 may provide a suitable alternative to autologous iliac bone graft, with the possible advantages of shorter operative time and reduced intraoperative blood loss, and may be considered as part of the orthopedic surgeon's treatment options.
authors.affiliation: Premier Orthopaedics, Hendersonville, USA.
authors.forename: Marc A
authors.initials: MA
authors.lastname: Tressler
authors.forename: Justin E
authors.initials: JE
authors.lastname: Richards
authors.forename: D'mitri
authors.initials: D
authors.lastname: Sofianos
authors.forename: F Kyle
authors.initials: FK
authors.lastname: Comrie
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Kregor
authors.forename: William T
authors.initials: WT
authors.lastname: Obremskey
mesh_terms: D000328:Adult; D055396:Bone Morphogenetic Protein 2 / Q000627:therapeutic use*; D016025:Bone Transplantation / Q000379:methods*; D005260:Female; D005264:Femoral Fractures / Q000628:therapy; D017102:Fracture Healing / Q000187:drug effects; D005599:Fractures, Ununited / Q000628:therapy*; D006801:Humans; D006810:Humeral Fractures / Q000628:therapy*; D007085:Ilium / Q000637:transplantation*; D007869:Leg Injuries / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012189:Retrospective Studies; D013978:Tibial Fractures / Q000628:therapy; D014182:Transplantation, Autologous
chemical_list: C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D011994:Recombinant Proteins